- Home
- FFIN vs GH Comparison
FFIN vs GH Comparison
Compare FFIN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFIN
- GH
- Stock Information
- Founded
- FFIN 1890
- GH 2011
- Country
- FFIN United States
- GH United States
- Employees
- FFIN N/A
- GH N/A
- Industry
- FFIN Major Banks
- GH Medical Specialities
- Sector
- FFIN Finance
- GH Health Care
- Exchange
- FFIN Nasdaq
- GH Nasdaq
- Market Cap
- FFIN 5.3B
- GH 4.9B
- IPO Year
- FFIN N/A
- GH 2018
- Fundamental
- Price
- FFIN $35.26
- GH $40.62
- Analyst Decision
- FFIN Hold
- GH Strong Buy
- Analyst Count
- FFIN 4
- GH 21
- Target Price
- FFIN $39.00
- GH $52.81
- AVG Volume (30 Days)
- FFIN 451.6K
- GH 2.3M
- Earning Date
- FFIN 07-17-2025
- GH 04-30-2025
- Dividend Yield
- FFIN 2.15%
- GH N/A
- EPS Growth
- FFIN 16.55
- GH N/A
- EPS
- FFIN 1.62
- GH N/A
- Revenue
- FFIN $553,583,000.00
- GH $773,996,000.00
- Revenue This Year
- FFIN $19.60
- GH $23.05
- Revenue Next Year
- FFIN $5.84
- GH $21.40
- P/E Ratio
- FFIN $21.77
- GH N/A
- Revenue Growth
- FFIN 13.33
- GH 28.20
- 52 Week Low
- FFIN $27.62
- GH $20.14
- 52 Week High
- FFIN $44.66
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- FFIN 53.84
- GH 48.45
- Support Level
- FFIN $34.01
- GH $37.73
- Resistance Level
- FFIN $36.67
- GH $39.63
- Average True Range (ATR)
- FFIN 0.79
- GH 1.60
- MACD
- FFIN -0.04
- GH -0.01
- Stochastic Oscillator
- FFIN 55.80
- GH 60.00
About FFIN First Financial Bankshares Inc.
First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto. It derives maximum revenue from Construction and Development Segment.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.